The minimum inhibitory concentration (MIC) is the lowest concentration of an antimicrobial agent that prevents visible growth of a microorganism under specified laboratory conditions. It is a quantitative measure used in antimicrobial susceptibility testing, particularly for bacteria and fungi. An MIC describes inhibition in a particular test system; it does not by itself establish that the organism has been killed or that an infection will respond to treatment.
Definition and units
An MIC is determined for a particular combination of microbial isolate, antimicrobial agent, test method, growth medium, and incubation conditions. It is therefore not an unchanging property of a drug or microbial species.
Results are commonly expressed in milligrams per litre (mg/L) or micrograms per millilitre (µg/mL), which are numerically equivalent:
In a conventional dilution test, the organism is exposed to a series of antimicrobial concentrations. The MIC is the lowest tested concentration meeting the specified growth-inhibition endpoint. For many antibacterial tests, that endpoint is the absence of visible growth. Some organism–drug combinations, particularly in antifungal testing, use a defined reduction in growth rather than complete visual inhibition.
A lower MIC indicates that less of an agent was required to inhibit the tested isolate under those conditions. It does not necessarily mean that one drug is clinically superior to another, because achievable exposure, dosing, toxicity, and interpretive criteria differ between drugs.
Measurement methods
Broth dilution
Broth dilution exposes a standardized microbial inoculum to antimicrobial concentrations in a liquid growth medium. Broth microdilution uses small volumes in microplate wells; broth macrodilution uses larger volumes, commonly in tubes. Broth microdilution is a reference method for many bacterial susceptibility tests.
Concentrations usually follow a twofold dilution series, such as 0.25, 0.5, 1, 2, and 4 mg/L. After a defined incubation period, growth is compared with appropriate controls. A growth control without antimicrobial confirms that the organism can grow, while an uninoculated control helps detect contamination or problems with the medium.
If growth occurs at 1 mg/L but not at 2 mg/L, the reported MIC is 2 mg/L. This is a discrete test endpoint, not proof that the exact biological threshold is precisely 2 mg/L. If all tested concentrations inhibit growth, the result is reported as less than or equal to the lowest concentration tested; if none inhibits growth, it is reported as greater than the highest concentration tested.
Agar dilution
In agar dilution, different antimicrobial concentrations are incorporated into solid growth medium. Standardized inocula are applied to the agar surface, and the MIC is determined from the lowest concentration meeting the prescribed inhibition endpoint. This method permits multiple isolates to be tested on the same plate.
Gradient diffusion and automated systems
Gradient diffusion uses a strip containing a continuous antimicrobial gradient placed on inoculated agar. As the antimicrobial undergoes diffusion, an inhibition zone develops. The MIC is read where the zone boundary intersects the strip’s concentration scale, according to method-specific rules.
Automated systems use defined concentration panels and instrument-based growth detection to determine or estimate MICs. Their results require validation against appropriate reference methods. Not every method is interchangeable for every organism–drug combination.
Ordinary disk diffusion measures inhibition-zone diameter rather than MIC. Zone diameters can support susceptibility categorization using validated criteria, but they are not direct MIC measurements.
Standardization and measurement variability
Reliable testing depends on controlling inoculum density, medium composition, pH, temperature, incubation duration, atmosphere, and endpoint interpretation. Some agents also require control of particular ions or other medium constituents.
Organizations including the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) publish standardized methods and interpretive criteria.
MIC testing has inherent measurement uncertainty. Small differences between repeat measurements, often one step in a twofold dilution series, may reflect normal test variability rather than a meaningful biological change. Quality-control strains with established acceptable ranges help laboratories monitor test performance.
Other complications include indistinct or trailing growth, contamination, unusually large inocula, and resistant subpopulations within an apparently susceptible culture.
Clinical interpretation
An MIC becomes clinically interpretable when compared with an appropriate clinical breakpoint: a threshold used to assign susceptibility categories for a specified organism–drug combination. Breakpoints incorporate microbiological data, drug exposure, pharmacokinetics, pharmacodynamics, and clinical evidence. They may depend on dosing regimens or infection site.
Categories commonly include susceptible, intermediate, and resistant, but their definitions differ between systems. In EUCAST terminology, I means “susceptible, increased exposure,” rather than simply an indeterminate category. Category labels therefore require the accompanying standard and version for precise interpretation.
A clinical breakpoint is distinct from an epidemiological cutoff value. An epidemiological cutoff separates the wild-type MIC distribution from isolates with phenotypically detectable acquired resistance mechanisms; it does not directly predict treatment success.
MIC results are one input to clinical assessment, not a stand-alone prediction. Drug penetration into the infection site, host immune function, and other features of the infection can affect outcomes.
Relationship to resistance and antimicrobial exposure
An elevated MIC can be associated with antimicrobial resistance mechanisms such as drug-inactivating enzymes, altered drug targets, reduced entry, or increased efflux. These mechanisms may involve mutations or genes acquired through horizontal gene transfer. An MIC alone generally does not identify the underlying mechanism.
MIC is also used in pharmacokinetic–pharmacodynamic indices, including:
- the fraction of a dosing interval during which unbound drug concentration exceeds the MIC;
- the ratio of peak drug concentration to MIC;
- the ratio of the area under the concentration–time curve to MIC.
Which index best relates to antimicrobial activity depends on the agent and organism. Such indices connect laboratory inhibition measurements with changing drug exposure in the body.
Related measurements and limitations
The minimum bactericidal concentration (MBC) measures a different endpoint: the lowest concentration producing a specified reduction in viable bacteria, conventionally at least 99.9% of the starting inoculum under defined conditions. Organisms may remain viable despite showing no visible growth at the MIC.
MIC50 and MIC90 describe isolate populations. They are the MIC values at or below which 50% and 90% of tested isolates, respectively, are inhibited. They do not mean 50% or 90% growth inhibition within a single culture and are not equivalent to an IC50 from a concentration–response experiment.
Standard MIC assays usually examine freely growing organisms under controlled laboratory conditions. They do not fully reproduce tissue environments, mixed microbial communities, or biofilms. Antimicrobial tolerance and persistence can also affect survival during exposure without necessarily producing an increased MIC. Consequently, MIC measurements quantify a defined growth-inhibition endpoint rather than every aspect of microbial survival or treatment response.